The area of adverse drug reactions (ADR) is considered of secondary importance in the list of topics in biomedicine. This has reduced the study of ADR to a boring analysis of reports in the effort to ascribe causal relations to drugs under study. In order to upgrade the study of ADR the scientific community must become much more involved since ADR are in fact a complementary aspect of efficacy, and are an essential factor for evaluating the benefit-risk ratio. The following aspects will be discussed with examples. • ADR should not be a passive collection of spontaneous reports but should involve active research, with the development and of suitable methods. • ADR should be an essential teaching subject in pharmacology and therapeutics, introducing the value of these studies as a basis for understanding other aspects of the mechanism of action of each drug. • Scientists must be stimulated to investigate the mechanisms involved in ADR, specifically looking at how to counteract them. Pharmacogenetics and pharmacogenomics could be important approaches for predicting ADR. Drug interactions could be a major factor in ADR. • An ADR data-base should be the established at the European level in order to assure rapid detection of relatively rare ADR.
|Journal||European Journal of Clinical Pharmacology|
|Publication status||Published - 2001|
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)